Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...
IFLScience on MSN6h
Inhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
GlobalData on MSN13h
Boehringer and partners commence gene therapy trial for cystic fibrosisBoehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...
An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
president and CEO of the Cystic Fibrosis Foundation in Bethesda, Maryland. The disease impacts the lungs by clogging airways with sticky, thick mucus, which traps bacteria and other germs and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback